Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

J&J Seeking FDA Approval For Authorization Of Its COVID-19 Vaccine Booster

By John F. Heerdink, Jr.

As per reports, Johnson & Johnson has submitted data to the U.S. Food and Drug Administration for emergency use authorization of a booster shot of its COVID-19 vaccine in people aged 18 and above. The submission includes data from a late-stage study reporting a booster given 56 days after the first dose provided 94% protection against symptomatic COVID-19 in the United States and 100% safety at least 14 days after the booster shot.

The authority has already authorized a booster dose of the vaccine developed by Pfizer Inc and partner BioNTech for 65-year olds and older, for those at high risk of severe disease, and others regularly exposed to the virus. Rival vaccine maker Moderna has also submitted an application seeking authorization for a booster shot of its two-dose vaccine last month.

J&J is also planning to submit the data to other regulators, the National Immunization Technical Advisory Groups, the World Health Organization to inform decision-making on local vaccine administration strategies, as needed.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

(Read Original Story: UPDATE 2-J&J files for authorization of COVID-19 vaccine booster in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us